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EFV/FTC/TDF for first-line HIV treatment. In scenario analysis assuming 
equivalent efficacy, EFV/FTC/TDF dominated EVG/cobi/FTC/TDF with lower costs 
and greater QALYs.  
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OBJECTIVES: The objective of this research is to evaluate the cost-effectiveness 
of linezolid 600mgBID(LI), vancomycin 1gBID(VA) and teicoplanin 400mgBID(TE) 
in the treatment of nosocomial pneumonia caused by MRSA under the public 
health care system perspective. METHODS: To compare the options, a decision 
tree model was built considering an arm per treatment option, from which 
patients could respond to the initial treatment and continue to a maintenance 
treatment using the same antibiotics, or do not respond, and repeat the 
treatment with assumed 50% chance to use one of the other two antibiotics. 
Clinical or microbiological effectiveness could be used as determinants of 
response. Effectiveness measures were mortality, clinical and microbiological 
responses, calculated by an indirect comparison of a literature systematic 
review. Hospitalization days were evaluated. Only direct costs were considered, 
and were obtained from DATASUS/SIGTAP 2012 for medical procedures,  
and DATASUS/BPS considering the average of purchases from November 2011 to 
October 2012 for medications and materials, as the latest data available. Values 
were represented in 2012USD. A time horizon of 1 year was considered. 
RESULTS: Clinical response rates were 66.5%(VA), 68.3%(TE), 72.6%(LI), 
microbiological response rates were 56.1%(VA), 55.9%(TE), 64.4%(LI), mortality 
rates were 15.74%(VA), 13.56%(TE), 10.13%(LI). If clinical response was considered 
as a determinant of success, the treatment costs would be 13,806.58USD(VA), 
14,279.01USD(TE), 15,301.44USD(LI), hospitalization days would be 41(VA),  
39(TE), 26(LI), and if microbiological response was considered, the treatment 
costs would be 14,637.39USD(VA); 15,169.33USD(TE), 15,793.21USD(LI) and 
hospitalization days would be 42(VA), 40(TE), 28(LI). Incremental cost-
effectiveness ratios for TE and LI when compared to VA for clinical response 
were 26,246.03USD, 24,505.90USD, and for microbiological response were  
-26,597.03USD(dominated), 13,925.46USD respectively. CONCLUSIONS: Assuming 
a willingness to pay of 32,621.93USD (3 times Brazilian 2011GDP per capita), 
linezolid was the most cost-effective option compared to vancomycin, 
additionally presenting lower mortality and less hospitalization days at public 
health care services.  
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OBJECTIVES: Clinically, interferon-alpha (IFN-α) is used for inhibiting hepatitis B 
and C virus infection, but IFN-α treatment may cause side effects of depression. 
Recent study has reported that serum serotonin levels are associated with 
antiviral therapy outcomes in patients with chronic hepatitis C. The aim of this 
study was to evaluate the cost and effectiveness of antidepressants in hepatitis C 
patients treated with interferon. METHODS: This is a retrospective study from 
January 1, 2002 to December 31, 2010 using Chi-Mei Medical Center claim data. 
Subjects were divided into exposure and control groups. The exposure group 
included patients treated with IFN-α or combined antiviral drugs and 
antidepressants for at least 6 months. The control group was those without 
antidepressant treatment. The endpoints were evaluated liver related lab data, 
the number of visits to the out-patient department, emergency department or 
admission during treatment, and the cost. RESULTS: There were a total of 135 
patient diagnosed hepatitis B or C and treated with IFN-α or combined antiviral 
drugs. Comparing the exposure and control groups, the control group had a 
higher SGOT (53.97±40.0 vs. 93.16±64.54 IU/L, 95% CI=28.12~50.3, P<0.05); SGPT 
(62.07±5. IU/L vs. 316.36±123.4 IU/L, 95% CI=79.95~122.64, P<0.05), AFP (9.8±22.4 
ng/mL vs. 11.79±18.1 ng/mL, 95% CI=-1.77~5.7, P=0.304). Comparing mean health 
care costs in six months is NT 263,200 for exposure group and 242,600 for control 
group. No significant difference. That may be related to psychiatric visits and 
medication use. CONCLUSIONS: These results suggest that antidepressants may 
play an important role in hepatitis B or C patients treated with IFN-α or 
combined antiviral drugs. Future studies are needed to further clarify the 
mechanisms of antidepressant action.  
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OBJECTIVES: A pneumococcal 7-valent conjugate vaccine (PCV7) was launched 
as a Category II vaccine requiring out-of-pocket payment in China in 2008. The 
objective of this study was to estimate the expected health benefits, cost, and 
incremental cost-effectiveness of introducing a public financed City 
Immunization Program (CIP) to pay for PCV7 from a social perspective in the long 
term. METHODS: A Markov cohort model was used to estimate cost and 
epidemiological burden of invasive pneumococcal disease (IPD), pneumonia and 
otitis media for all age cohort in Beijing, Guangzhou, Shenzhen and Wuhan 
within five years. Data includes cost data from eight hospitals in four cities as 
well as epidemiological data from Bureau of National Health Insurance in 
Taiwan. Outcomes were measured by reduction in disease burden, cost, quality-
adjusted life years (QALYs) and incremental cost-effectiveness ratio. In addition 
we performed sensitivity analyses for key parameters. RESULTS: Due to this 
immunization program, 11793 people may avoid dying, 42265.49 QALYs were 
generated additionally in the four cities within five years. Besides, this program 
may reduce the disease burden about RMB 1,574.7 per person. CONCLUSIONS: 
Integrating PCV7 into CIP has remarkable cost-effectiveness. It would possibly 
bring more net benefit with the increasing rate of immunization.  
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OBJECTIVES: Streptococcus pneumoniae is an important gram-positive pathogen 
with more than 90 serotypes, responsible for invasive pneumococcal diseases 
(IPD) (meningitis, bacteremia) and noninvasive diseases (pneumonia, otitis acute 
middle [OAM]). This analysis is aimed to estimate the cost-effectiveness of 
pneumococcal conjugate vaccines PCV13 and PCV10 in terms of prevention of 
diseases and deaths by IPD, radiologically confirmed pneumonia, AOM, and life 
years gained (LYG) in a cohort of newborns in Colombia. METHODS: A decision 
tree was developed with national data including the distribution of 
pneumococcal serotypes in Colombia between 2009 and 2011. Comparators were: 
PCV13, PCV10 (scheme 2 + 1) against no vaccination; vaccine coverage of 90 % 
was assumed (699,975 children). The simulation of newborns in Colombia took 
place within a time horizon of 5 years and a discount rate of 3%. The analysis 
used the third-party payer perspective. The efficacy values of the vaccines were 
determined by a systematic review. Medical costs are expressed in 2012 US$ and 
were provided by “SURA” a Colombian health insurance company. Probabilistic 
sensitivity analyses for epidemiological, efficacy and cost parameters were 
performed. RESULTS: After 5 years of follow-up, PCV13 would prevent 426 deaths 
due to pneumococcal infections versus 331 that would be prevented by PCV10, 
compared to no vaccination. PCV13 and PCV10 would generate 25,212 LYG and 
19,584 LYG, respectively. Medical costs avoided would be US$19,920,837 and 
US$15,094,775, respectively. Compared to no vaccination, PCV13 and PCV10 were 
cost-effective, with cost-effectiveness ratio of US$570.35 and US$768.57 per LYG; 
although, PCV13 was dominant over PCV10 due to lower total costs and better 
health outcomes. CONCLUSIONS: PCV13 is a cost-saving strategy compared with 
PCV10, as part of a mass vaccination program in Colombian children under one 
year. PCV13 is expected to lead to a greater decrement in infant mortality from 
pneumococcal diseases.  
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OBJECTIVES: In 2012, the U.S. Advisory Committee on Immunization Practices 
(ACIP) revised their 1997 adult pneumococcal vaccination recommendations to 
include a sequential regimen of 13-valent pneumococcal conjugate vaccine 
(PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for 
certain high-risk adults with immunocompromising conditions, while 
continuing routine PPSV23 use for healthy and immunocompetent adults with 
comorbidities. This study aims to examine: 1) cost-effectiveness of the 2012 ACIP 
recommendations relative to 1997 recommendations; 2) cost-effectiveness of 
potential future pneumococcal vaccination policies; 3) key assumptions that 
influence study results. METHODS: A static cohort model that incorporated 
costs, health outcomes, and quality-adjusted life-year (QALY) losses associated 
with invasive pneumococcal disease and non-bacteremic pneumococcal 
pneumonia (NBPP) was developed to evaluate the cost-effectiveness of seven 
pneumococcal vaccination strategies for an adult cohort 50 years of age using 
incremental cost-effectiveness ratios (ICERs). RESULTS: For aim 1, the 2012 ACIP 
recommendation was found to be the most economically efficient strategy (ICER 
of $14,781 per QALY gained). For aim 2, when the set of strategies evaluated was 
broadened to consider potential future policies, the most economically efficient 
strategy was modifying the 2012 recommendation for adults with 
immunocompromising conditions to include a sequential regimen of PCV13 and 
PPSV23 (ICER of $13,775 per QALY gained). For aim 3, cost-effectiveness ratios for 
alternative vaccination strategies were highly influenced by assumptions about 
vaccine effectiveness in NBPP and accounting for herd protection effects of 
pediatric pneumococcal vaccination on adult pneumococcal disease. 
CONCLUSIONS: Extending the 2012 ACIP recommendation to include a 
sequential regimen of PCV13 and PPSV23 at age 65 for adults with 
immunocompromising conditions appears to be a cost-effective vaccination 
policy. Given the uncertainty in available data and absence of key influential 
data related to vaccine effectiveness and herd protection, policy-makers should 
conduct comprehensive sensitivity analyses when evaluating new 
pneumococcal vaccine strategies in adults.  
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OBJECTIVES: Guidelines for management of genotype 1 chronic hepatitis C (CH-
C) patients recommend a liver biopsy and treating patients with significant 
